nanotech investing Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
nanotech investing Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
nanotech investing Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine Candidate
nanotech investing Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
nanotech investing Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
nanotech investing Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
nanotech investing Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
nanotech investing Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
nanotech investing Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
Precipitate Gold Strengthens Board with Appointment of Dominican Business Leader Pelayo Troncoso and Mining Finance Executive John Wenger
America Needs Antimony, and This Nevada Explorer Just Defined One of the Largest Domestic Resources of It
